RESEARCH TRIANGLE PARK – Drug giant Merck reportedly is in talks to acquire biotech firm Seagen in a deal that could be worth as much as $40 billion.
So reports The Wall Street Journal and Fox News.
Seagen is primarily focused on cancer research and drugs.
Merck operates big plants in Durham and Wilson.
